Biocartis strengthens management team with Chief Medical Officer

Stefan Scherer joins Biocartis most recently from Hoffmann-La Roche/Genentech, where he held several functions since 2006. In 2010 he was appointed Global Biomarker Head Oncology. His responsibilities included overall accountability for the global biomarker and translational medicine development programs as well as medical affairs activities.
 
Prior to joining Genentech, Stefan worked at Grunenthal, Inc., a development partner of Johnson & Johnson, as an International Clinical Project Leader & Clinical Expert. His scientific career was spent at the Albert Einstein College of Medicine in New York (USA) and the University of Wuerzburg (Germany), where he elucidated novel functions of DNA repair in hereditary cancers.
 
At Biocartis Stefan Scherer will be a member of Biocartis’ Executive Committee. “Stefan has been championing the use of diagnostic biomarkers in oncology therapy for most of his career. As an MD, Stefan brings us a passion for delivering practical, clinically useful tests improving treatments for cancer patients," commented Greg Parekh, Chief Executive Officer of Biocartis.
 
Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis’ ambition is to establish a new gold standard in diagnostic testing.